Search

Search Constraints

You searched for: Author/Creator Pyo, Kyoung-Ho

Search Results

1. 363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result. (9th November 2020)

2. 363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result. (9th November 2020)

3. 572 Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TMEkine™ potentiates anti-cancer effects in preclinical cancer models. (9th November 2020)

4. Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer. (August 2021)

5. Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer. Issue 2 (29th July 2020)

6. Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. (January 2021)

7. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. (May 2016)

8. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. (October 2018)

10. Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. (February 2022)